Moderna reports Q3 profit and raises 2026 revenue-growth outlook
+2 new sources since this summary was written
Moderna reported third-quarter 2026 GAAP diluted EPS of $0.38 and net income of $162 million, reversing the prior-year loss. The company raised its 2026 expected revenue growth to 15%-25%, above its previous expectation of up to 10% growth. It also increased expected year-end cash to $8.1-$8.3 billion and highlighted FDA approval of mFLUSIVA and positive Phase 3 results for intismeran.
Why it matters
The higher revenue-growth range changes Moderna's stated 2026 financial framework, while the increased cash range raises its projected year-end liquidity. The results also add approved and late-stage products to the company's commercial and pipeline updates.
Key facts
- 1Moderna reported GAAP diluted EPS of $0.38 for the third quarter of 2026. finanznachrichten.de
- 2Third-quarter net income was $162 million, compared with a net loss of $(200) million in the third quarter of 2025. finanznachrichten.de
- 3Moderna increased its 2026 expected revenue growth to 15%-25% from a previous expectation of up to 10% growth. finanznachrichten.de
- 4The company raised its expected ending cash balance for 2026 to $8.1-$8.3 billion. finanznachrichten.de
- 5Moderna said mFLUSIVA received U.S. FDA approval and that intismeran produced positive Phase 3 data. finanznachrichten.de
Open questions
- Material 15 reports Q3 revenue as $1.31M and describes it as below expectations, while the other detailed materials report billion-dollar revenue and an estimate beat; the discrepancy is unresolved.
Summary written by AlphAI AI Desk from 20 of 30 sources. Not investment advice. Figures are as stated by the linked sources.